These are the stocks posting the largest moves before the bell.Market Insiderread more
The next three weeks are among the rockiest, on a historical basis, of the entire calendar.Trading Nationread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Microsoft is looking for a new way to grab business from retailers as they fend off Amazon.Technologyread more
Banks have historically used armies of mortgage brokers to gather income and asset documents from prospective borrowers.Financeread more
Worries over global economic growth were set to thwart Wall Street's run to record highs on Monday.Marketsread more
Guggenheim reiterates its buy rating on Boston Beer's stock and raises its price target to $462 from $449 per share.Investingread more
On-demand delivery company Postmates is partnering with Phantom Auto, an autonomous vehicle teleoperator, to coordinate driverless deliveries.Autosread more
Bruce Broussard, CEO of health insurance company Humana, sits down with CNBC's Bertha Coombs to discuss the state of the industry, integrating digital health technology,...Squawk Boxread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
Here are the biggest calls on Wall Street on MondayInvestingread more
Check out the companies making headlines after the bell:
Tilray shares surged as much as 19 percent after hours after the company announced it entered into a $100 million joint venture with AB InBev. The beer brewer and Tilray will study non-alcoholic cannabis-based beverages in Canada. The joint venture, in which both companies will invest $50 million each, will study non-alcoholic beverages containing THC, the intoxicating chemical compound in marijuana, as well as CBD, the non-psychoactive compound.
Spectrum Pharmaceuticals shares plummeted nearly 34 percent during after hours trading upon the news that the U.S. Food and Drug Administration did not grant Breakthrough Therapy Designation to the drug poziotinib. This treats patients with non-small cell lung cancer. This designation would've expedited the review of the drug.
Steelcase shares rose as much as 2.3 percent during after hours trading as the company beat expectations on its top and bottom lines. The company earned 36 cents per share, while analysts expected 30 cents per share. It also beat estimates of $898 million in revenue, reporting $901 million this quarter.